Targeting cell cycle regulators in hematologic malignancies

Frontiers in Cell and Developmental Biology

Volumn 3, Issue APR, 2015, Pages

  Aleem, Eiman ^a,b   Arceci, Robert J ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Alexandria University Faculty Of Science   (Egypt)

Author keywords

Cdk1; Cdk19; Cdk6; Cdk8; Cyclin C; Leukemia; Mouse models; Wee 1

Indexed keywords

EID: 84941337346     PISSN: None     EISSN: 2296634X     Source Type: Journal    
DOI: 10.3389/fcell.2015.00016     Document Type: Review

References (291)

1. Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., et al. (2012). Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2, 524-539. doi: 10.1158/2159-8290.CD-11-0320
2. Agirre, X., Vilas-Zornoza, A., Jimenez-Velasco, A., Martin-Subero, J. I., Cordeu, L., Garate, L., et al. (2009). Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69, 4443-4453. doi: 10.1158/0008-5472.CAN-08-4025
3. Akoulitchev, S., Chuikov, S., and Reinberg, D. (2000). TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 407, 102-106. doi: 10.1038/35024111
4. Alarcon, C., Zaromytidou, A. I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., et al. (2009). Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 139, 757-769. doi: 10.1016/j.cell.2009.09.035
5. Aleem, E., and Kaldis, P. (2006). Mouse models of cell cycle regulators: new paradigms. Results Probl. Cell Differ. 42, 271-328. doi: 10.1007/400_023
6. Aleem, E., Kiyokawa, H., and Kaldis, P. (2005). Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat. Cell Biol. 7, 831-836. doi: 10.1038/ncb1284
7. Ali, F., Hindley, C., Mcdowell, G., Deibler, R., Jones, A., Kirschner, M., et al. (2011). Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with differentiation during neurogenesis. Development 138, 4267-4277. doi: 10.1242/dev.067900
8. Alt, J. R., Cleveland, J. L., Hannink, M., and Diehl, J. A. (2000). Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14, 3102-3114. doi: 10.1101/gad.854900
9. Alvarez-Fernandez, S., Ortiz-Ruiz, M. J., Parrott, T., Zaknoen, S., Ocio, E. M., San Miguel, J., et al. (2013). Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin. Cancer Res. 19, 2677-2687. doi: 10.1158/1078-0432.CCR-12-2118
10. Antony-Debre, I., and Steidl, U. (2014). CDK6, a new target in MLL-driven leukemia. Blood 124, 5-6. doi: 10.1182/blood-2014-05-572917
11. Appelbaum, F. R., Rosenblum, D., Arceci, R. J., Carroll, W. L., Breitfeld, P. P., Forman, S. J., et al. (2007). End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109, 1810-1816. doi: 10.1182/blood-2006-08-041152
12. Arceci, R. J., and Aplenc, R. (2009). "Acute myelogenous leukemia in children," in Wintrobe's Clinical Hematology, 12th Edn., eds J. P. Greer, J. Foerster, and G. M. Rodgers (Philadelphia, PA: Lippincott Williams & Wilkins), 1918-1937.
13. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., et al. (1998). Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91, 2482-2490.
14. Baker, S. J., and Reddy, E. P. (2012). CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer 3, 658-669. doi: 10.1177/1947601913478972
15. Banks, A. S., Mcallister, F. E., Camporez, J. P., Zushin, P. J., Jurczak, M. J., Laznik-Bogoslavski, D., et al. (2015). An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma. Nature 517, 391-395. doi: 10.1038/nature13887
16. Bartkowiak, B., Liu, P., Phatnani, H. P., Fuda, N. J., Cooper, J. J., Price, D. H., et al. (2010). CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 24, 2303-2316. doi: 10.1101/gad.1968210
17. Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., et al. (2006). A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66, 7661-7667. doi: 10.1158/0008-5472.CAN-06-1098
18. Bergsagel, P. L., and Kuehl, W. M. (2001). Chromosome translocations in multiple myeloma. Oncogene 20, 5611-5622. doi: 10.1038/sj.onc.1204641
19. Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., et al. (2010). The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905. doi: 10.1038/nature08822
20. Berthet, C., Aleem, E., Coppola, V., Tessarollo, L., and Kaldis, P. (2003). Cdk2 knockout mice are viable. Curr. Biol. 13, 1775-1785. doi: 10.1016/j.cub.2003.09.024
21. Berthet, C., Rodriguez-Galan, M. C., Hodge, D. L., Gooya, J., Pascal, V., Young, H. A., et al. (2007). Hematopoiesis and thymic apoptosis are not affected by the loss of Cdk2. Mol. Cell. Biol. 27, 5079-5089. doi: 10.1128/MCB.00029-07
22. Bertoni, F., Rinaldi, A., Zucca, E., and Cavalli, F. (2006). Update on the molecular biology of mantle cell lymphoma. Hematol. Oncol. 24, 22-27. doi: 10.1002/hon.767
23. Betticher, D. C., Thatcher, N., Altermatt, H. J., Hoban, P., Ryder, W. D., and Heighway, J. (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11, 1005-1011.
24. Biggs, J. R., Peterson, L. F., Zhang, Y., Kraft, A. S., and Zhang, D. E. (2006). AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol. Cell. Biol. 26, 7420-7429. doi: 10.1128/MCB.00597-06
25. Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., et al. (2011). The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25, 2158-2172. doi: 10.1101/gad.16962311
26. Bose, P., Simmons, G. L., and Grant, S. (2013). Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin. Investig. Drugs 22, 723-738. doi: 10.1517/13543784.2013.789859
27. Boutros, R., Lobjois, V., and Ducommun, B. (2007). CDC25 phosphatases in cancer cells: key players? Good targets? Nat. Rev. Cancer 7, 495-507. doi: 10.1038/nrc2169
28. Bradford, G. B., Williams, B., Rossi, R., and Bertoncello, I. (1997). Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp. Hematol. 25, 445-453.
29. Brito-Babapulle, V., Gruszka-Westwood, A. M., Platt, G., Andersen, C. L., Elnenaei, M. O., Matutes, E., et al. (2002). Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. Haematologica 87, 357-362. Available online at: http://www.haematologica.org/content/87/4/357.long
30. Brower, V. (2014). Cell cycle inhibitors make progress. J. Natl. Cancer Inst. 160:dju221. doi: 10.1093/jnci/dju221
31. Bruyere, C., and Meijer, L. (2013). Targeting cyclin-dependent kinases in anti-neoplastic therapy. Curr. Opin. Cell Biol. 25, 772-779. doi: 10.1016/j.ceb.2013.08.004
32. Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., et al. (2007). Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109, 399-404. doi: 10.1182/blood-2006-05-020735
33. Byrd, J. C., Peterson, B. L., Gabrilove, J., Odenike, O. M., Grever, M. R., Rai, K., et al. (2005). Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin. Cancer Res. 11, 4176-4181. doi: 10.1158/1078-0432.CCR-04-2276
34. Cabezas-Wallscheid, N., Klimmeck, D., Hansson, J., Lipka, D. B., Reyes, A., Wang, Q., et al. (2014). Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA Methylome analysis. Cell Stem Cell 15, 507-522. doi: 10.1016/j.stem.2014.07.005
35. Caldwell, J. T., Edwards, H., Buck, S. A., Ge, Y., and Taub, J. W. (2014). Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr. Blood Cancer 61, 1767-1773. doi: 10.1002/pbc.25081
36. Carrassa, L., Chila, R., Lupi, M., Ricci, F., Celenza, C., Mazzoletti, M., et al. (2012). Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 11, 2507-2517. doi: 10.4161/cc.20899
37. Castro-Gamero, A. M., Borges, K. S., Moreno, D. A., Suazo, V. K., Fujinami, M. M., De Paula Gomes Queiroz, R., et al. (2013). Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells. Invest. New Drugs 31, 858-870. doi: 10.1007/s10637-012-9917-4
38. Chao, S. H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., et al. (2000). Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275, 28345-28348. doi: 10.1074/jbc. C000446200
39. Chao, S. H., and Price, D. H. (2001). Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276, 31793-31799. doi: 10.1074/jbc. M102306200
40. Chen, E. X., Hotte, S., Hirte, H., Siu, L. L., Lyons, J., Squires, M., et al. (2014). A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. Br. J. Cancer 111, 2262-2267. doi: 10.1038/bjc.2014.565
41. Chen, H., Huang, Q., Dong, J., Zhai, D. Z., Wang, A. D., and Lan, Q. (2008). Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer 8:29. doi: 10.1186/1471-2407-8-29
42. Chen, S., Bohrer, L. R., Rai, A. N., Pan, Y., Gan, L., Zhou, X., et al. (2010). Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol. 12, 1108-1114. doi: 10.1038/ncb2116
43. Chen, X., Niu, H., Chung, W. H., Zhu, Z., Papusha, A., Shim, E. Y., et al. (2011). Cell cycle regulation of DNA double-strand break end resection by Cdk1-dependent Dna2 phosphorylation. Nat. Struct. Mol. Biol. 18, 1015-1019. doi: 10.1038/nsmb.2105
44. Chen, Y. J., Dominguez-Brauer, C., Wang, Z., Asara, J. M., Costa, R. H., Tyner, A. L., et al. (2009). A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J. Biol. Chem. 284, 30695-30707. doi: 10.1074/jbc. M109.007997
45. Cheng, S. W., Kuzyk, M. A., Moradian, A., Ichu, T. A., Chang, V. C., Tien, J. F., et al. (2012). Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II. Mol. Cell. Biol. 32, 4691-4704. doi: 10.1128/MCB.06267-11
46. Cheshier, S. H., Morrison, S. J., Liao, X., and Weissman, I. L. (1999). In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 96, 3120-3125. doi: 10.1073/pnas.96.6.3120
47. Chi, Y., Huddleston, M. J., Zhang, X., Young, R. A., Annan, R. S., Carr, S. A., et al. (2001). Negative regulation of Gcn4 and Msn2 transcription factors by Srb10 cyclin-dependent kinase. Genes Dev. 15, 1078-1092. doi: 10.1101/gad.867501
48. Chilosi, M., Doglioni, C., Yan, Z., Lestani, M., Menestrina, F., Sorio, C., et al. (1998). Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am. J. Pathol. 152, 209-217.
49. Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Bostrom, P., Laznik, D., et al. (2010). Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451-456. doi: 10.1038/nature09291
50. Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., et al. (2012). The requirement for cyclin D function in tumor maintenance. Cancer Cell 22, 438-451. doi: 10.1016/j.ccr.2012.09.015
51. Choi, Y. J., Saez, B., Anders, L., Hydbring, P., Stefano, J., Bacon, N. A., et al. (2014). D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. Dev. Cell 30, 255-267. doi: 10.1016/j.devcel.2014.06.015
52. Cirstea, D., Hideshima, T., Santo, L., Eda, H., Mishima, Y., Nemani, N., et al. (2013). Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia 27, 2366-2375. doi: 10.1038/leu.2013.194
53. Conway O'brien, E., Prideaux, S., and Chevassut, T. (2014). The epigenetic landscape of acute myeloid leukemia. Adv. Hematol. 2014:103175. doi: 10.1155/2014/103175
54. Costea, I., Moghrabi, A., and Krajinovic, M. (2003). The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics 13, 577-580. doi: 10.1097/00008571-200309000-00006
55. Davidson, G., Shen, J., Huang, Y. L., Su, Y., Karaulanov, E., Bartscherer, K., et al. (2009). Cell cycle control of wnt receptor activation. Dev. Cell 17, 788-799. doi: 10.1016/j.devcel.2009.11.006
56. De Klein, A., Van Kessel, A. G., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., et al. (1982). A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765-767. doi: 10.1038/300765a0
57. Della Ragione, F., Borriello, A., Mastropietro, S., Della Pietra, V., Monno, F., Gabutti, V., et al. (1997). Expression of G1-phase cell cycle genes during hematopoietic lineage. Biochem. Biophys. Res. Commun. 231, 73-76. doi: 10.1006/bbrc.1997.5938
58. Delmer, A., Ajchenbaum-Cymbalista, F., Tang, R., Ramond, S., Faussat, A. M., Marie, J. P., et al. (1995). Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85, 2870-2876.
59. De Witt Hamer, P. C., Mir, S. E., Noske, D., Van Noorden, C. J., and Wurdinger, T. (2011). WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin. Cancer Res. 17, 4200-4207. doi: 10.1158/1078-0432.CCR-10-2537
60. Dickson, M. A. (2014). Molecular pathways: CDK4 inhibitors for cancer therapy. Clin. Cancer Res. 20, 3379-3383. doi: 10.1158/1078-0432.CCR-13-1551
61. Diehl, J. A., Zindy, F., and Sherr, C. J. (1997). Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11, 957-972. doi: 10.1101/gad.11.8.957
62. Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., et al. (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510. doi: 10.1038/nature10738
63. Diril, M. K., Ratnacaram, C. K., Padmakumar, V. C., Du, T., Wasser, M., Coppola, V., et al. (2012). Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc. Natl. Acad. Sci. U.S.A. 109, 3826-3831. doi: 10.1073/pnas.1115201109
64. Do, K., Doroshow, J. H., and Kummar, S. (2013). Wee1 kinase as a target for cancer therapy. Cell Cycle 12, 3159-3164. doi: 10.4161/cc.26062
65. Donner, A. J., Ebmeier, C. C., Taatjes, D. J., and Espinosa, J. M. (2010). CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat. Struct. Mol. Biol. 17, U194-U199. doi: 10.1038/nsmb.1752
66. Donner, A. J., Szostek, S., Hoover, J. M., and Espinosa, J. M. (2007). CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol. Cell 27, 121-133. doi: 10.1016/j.molcel.2007.05.026
67. Drogat, J., Migeot, V., Mommaerts, E., Mullier, C., Dieu, M., Van Bakel, H., et al. (2012). Cdk11-cyclinL controls the assembly of the RNA polymerase II mediator complex. Cell Rep. 2, 1068-1076. doi: 10.1016/j.celrep.2012.09.027
68. Edgar, B. A., and Lehner, C. F. (1996). Developmental control of cell cycle regulators: a fly's perspective. Science 274, 1646-1652. doi: 10.1126/science.274.5293.1646
69. Elagib, K. E., Racke, F. K., Mogass, M., Khetawat, R., Delehanty, L. L., and Goldfarb, A. N. (2003). RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 101, 4333-4341. doi: 10.1182/blood-2002-09-2708
70. Elmlund, H., Baraznenok, V., Lindahl, M., Samuelsen, C. O., Koeck, P. J., Holmberg, S., et al. (2006). The cyclin-dependent kinase 8 module sterically blocks Mediator interactions with RNA polymerase II. Proc. Natl. Acad. Sci. U.S.A. 103, 15788-15793. doi: 10.1073/pnas.0607483103
71. Fabre, C., Gobbi, M., Ezzili, C., Zoubir, M., Sablin, M. P., Small, K., et al. (2014). Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemother. Pharmacol. 74, 1057-1064. doi: 10.1007/s00280-014-2583-9
72. Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., et al. (2008). CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455, 547-551. doi: 10.1038/nature07179
73. Flaherty, K. T., Lorusso, P. M., Demichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., et al. (2012). Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin. Cancer Res. 18, 568-576. doi: 10.1158/1078-0432.CCR-11-0509
74. Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., et al. (2004). Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427-1438.
75. Fryer, C. J., White, J. B., and Jones, K. A. (2004). Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol. Cell 16, 509-520. doi: 10.1016/j.molcel.2004.10.014
76. Furumoto, T., Tanaka, A., Ito, M., Malik, S., Hirose, Y., Hanaoka, F., et al. (2007). A kinase subunit of the human mediator complex, CDK8, positively regulates transcriptional activation. Genes Cells 12, 119-132. doi: 10.1111/j.1365-2443.2007.01036.x
77. Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., Del Prado, M., Lallena, M. J., et al. (2011). Abstract B233: identification and characterization of LY2835219: a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity. Mol. Cancer Ther. 10:B233. doi: 10.1158/1535-7163.TARG-11-B233
78. Gilliland, D. G., Jordan, C. T., and Felix, C. A. (2004). The molecular basis of leukemia. Hematology Am. Soc. Hematol. Educ. Program 2004, 80-97. doi: 10.1182/asheducation-2004.1.80
79. Goga, A., Yang, D., Tward, A. D., Morgan, D. O., and Bishop, J. M. (2007). Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 13, 820-827. doi: 10.1038/nm1606
80. Goh, K. C., Novotny-Diermayr, V., Hart, S., Ong, L. C., Loh, Y. K., Cheong, A., et al. (2012). TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 26, 236-243. doi: 10.1038/leu.2011.218
81. Gojo, I., and Karp, J. E. (2014). New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin. Cancer Res. 20, 6233-6241. doi: 10.1158/1078-0432.CCR-14-0900
82. Gojo, I., Sadowska, M., Walker, A., Feldman, E. J., Iyer, S. P., Baer, M. R., et al. (2013). Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother. Pharmacol. 72, 897-908. doi: 10.1007/s00280-013-2249-z
83. Gonzalez, D., Hamidi, N., Del Sol, R., Benschop, J. J., Nancy, T., Li, C., et al. (2014). Suppression of Mediator is regulated by Cdk8-dependent Grr1 turnover of the Med3 coactivator. Proc. Natl. Acad. Sci. U.S.A. 111, 2500-2505. doi: 10.1073/pnas.1307525111
84. Gordon, W. R., Arnett, K. L., and Blacklow, S. C. (2008). The molecular logic of Notch signaling-a structural and biochemical perspective. J. Cell Sci. 121, 3109-3119. doi: 10.1242/jcs.035683
85. Gorlick, R., Kolb, E. A., Houghton, P. J., Morton, C. L., Neale, G., Keir, S. T., et al. (2012). Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr. Blood Cancer 59, 1266-1274. doi: 10.1002/pbc.24073
86. Goyama, S., Schibler, J., Cunningham, L., Zhang, Y., Rao, Y., Nishimoto, N., et al. (2013). Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J. Clin. Invest. 123, 3876-3888. doi: 10.1172/JCI68557
87. Greenblatt, S. M., and Nimer, S. D. (2014). Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia 28, 1396-1406. doi: 10.1038/leu.2014.94
88. Growney, J. D., Shigematsu, H., Li, Z., Lee, B. H., Adelsperger, J., Rowan, R., et al. (2005). Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106, 494-504. doi: 10.1182/blood-2004-08-3280
89. Guen, V. J., Gamble, C., Flajolet, M., Unger, S., Thollet, A., Ferandin, Y., et al. (2013). CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc. Natl. Acad. Sci. U.S.A. 110, 19525-19530. doi: 10.1073/pnas.1306814110
90. Harada, Y., and Harada, H. (2011). Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations. J. Cell. Biochem. 112, 425-432. doi: 10.1002/jcb.22974
91. Harris, P. S., Venkataraman, S., Alimova, I., Birks, D. K., Balakrishnan, I., Cristiano, B., et al. (2014). Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol. Cancer 13:72. doi: 10.1186/1476-4598-13-72
92. Hashimoto, O., Shinkawa, M., Torimura, T., Nakamura, T., Selvendiran, K., Sakamoto, M., et al. (2006). Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 6:292. doi: 10.1186/1471-2407-6-292
93. Havelek, R., Cmielova, J., Kralovec, K., Bruckova, L., Bilkova, Z., Fousova, I., et al. (2014). Specific inhibition of Wee1 kinase and Rad51 recombinase: a strategy to enhance the sensitivity of leukemic T-cells to ionizing radiation-induced DNA double-strand breaks. Biochem. Biophys. Res. Commun. 453, 569-575. doi: 10.1016/j.bbrc.2014.09.123
94. Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., et al. (2000). Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19, 624-631. doi: 10.1038/sj.onc.1203354
95. Hedblom, A., Laursen, K. B., Miftakhova, R., Sarwar, M., Anagnostaki, L., Bredberg, A., et al. (2013). CDK1 interacts with RARgamma and plays an important role in treatment response of acute myeloid leukemia. Cell Cycle 12, 1251-1266. doi: 10.4161/cc.24313
96. Hirose, Y., and Ohkuma, Y. (2007). Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J. Biochem. 141, 601-608. doi: 10.1093/jb/mvm090
97. Hou, X., Wang, S., Zhou, Y., Xu, Z., Zou, Y., Zhu, X., et al. (2005). Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int. J. Hematol. 82, 206-209. doi: 10.1532/IJH97.A10418
98. Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G. F., et al. (2009). A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 69, 810-818. doi: 10.1158/0008-5472.CAN-08-2473
99. Huang, G., Zhao, X., Wang, L., Elf, S., Xu, H., Zhao, X., et al. (2011). The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood 118, 6544-6552. doi: 10.1182/blood-2010-11-317909
100. Huertas, P., Cortes-Ledesma, F., Sartori, A. A., Aguilera, A., and Jackson, S. P. (2008). CDK targets Sae2 to control DNA-end resection and homologous recombination. Nature 455, 689-692. doi: 10.1038/nature07215
101. Infante, J. R., Shapiro, G. I., Witteveen, P. O., Gerecitano, J. F., Ribrag, V., Chugh, R., et al. (2013). Abstract A276: phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. Mol. Cancer Ther. 12:A276. doi: 10.1158/1535-7163.TARG-13-A276
102. Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C., Lukas, J., et al. (2006). ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37-45. doi: 10.1038/ncb1337
103. Jena, N., Deng, M., Sicinska, E., Sicinski, P., and Daley, G. Q. (2002). Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res. 62, 535-541. Available online at: http://cancerres.aacrjournals.org/content/62/2/535.full
104. Jin, S., Zhao, H., Yi, Y., Nakata, Y., Kalota, A., and Gewirtz, A. M. (2010). c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J. Clin. Invest. 120, 593-606. doi: 10.1172/JCI38030
105. Jirawatnotai, S., Aziyu, A., Osmundson, E. C., Moons, D. S., Zou, X., Kineman, R. D., et al. (2004). Cdk4 is indispensable for postnatal proliferation of the anterior pituitary. J. Biol. Chem. 279, 51100-51106. doi: 10.1074/jbc. M409080200
106. Johnson, A. J., Yeh, Y. Y., Smith, L. L., Wagner, A. J., Hessler, J., Gupta, S., et al. (2012). The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 26, 2554-2557. doi: 10.1038/leu.2012.144
107. Johnson, N., Cai, D., Kennedy, R. D., Pathania, S., Arora, M., Li, Y. C., et al. (2009). Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol. Cell 35, 327-339. doi: 10.1016/j.molcel.2009.06.036
108. Jones, J. A., Kraut, E. H., Deam, D., Byrd, J. C., and Grever, M. R. (2012). Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia. Leuk. Lymphoma 53, 490-491. doi: 10.3109/10428194.2011.600484
109. Joshi, K. S., Rathos, M. J., Joshi, R. D., Sivakumar, M., Mascarenhas, M., Kamble, S., et al. (2007). In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol. Cancer Ther. 6, 918-925. doi: 10.1158/1535-7163.MCT-06-0613
110. Kaldis, P., and Aleem, E. (2005). Cell cycle sibling rivalry: Cdc2 vs. Cdk2. Cell Cycle 4, 1491-1494. doi: 10.4161/cc.4.11.2124
111. Kang, J., Sergio, C. M., Sutherland, R. L., and Musgrove, E. A. (2014). Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer 14:32. doi: 10.1186/1471-2407-14-32
112. Kannan, S., Sutphin, R. M., Hall, M. G., Golfman, L. S., Fang, W., Nolo, R. M., et al. (2013). Notch activation inhibits AML growth and survival: a potential therapeutic approach. J. Exp. Med. 210, 321-337. doi: 10.1084/jem.20121527
113. Karp, J. E., Blackford, A., Smith, B. D., Alino, K., Seung, A. H., Bolanos-Meade, J., et al. (2010). Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk. Res. 34, 877-882. doi: 10.1016/j.leukres.2009.11.007
114. Karp, J. E., Garrett-Mayer, E., Estey, E. H., Rudek, M. A., Smith, B. D., Greer, J. M., et al. (2012). Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica 97, 1736-1742. doi: 10.3324/haematol.2012.062539
115. Karp, J. E., Passaniti, A., Gojo, I., Kaufmann, S., Bible, K., Garimella, T. S., et al. (2005). Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin. Cancer Res. 11, 8403-8412. doi: 10.1158/1078-0432.CCR-05-1201
116. Karp, J. E., Ross, D. D., Yang, W., Tidwell, M. L., Wei, Y., Greer, J., et al. (2003). Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin. Cancer Res. 9, 307-315.
117. Karp, J. E., Smith, B. D., Levis, M. J., Gore, S. D., Greer, J., Hattenburg, C., et al. (2007). Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin. Cancer Res. 13, 4467-4473. doi: 10.1158/1078-0432.CCR-07-0381
118. Karp, J. E., Smith, B. D., Resar, L. S., Greer, J. M., Blackford, A., Zhao, M., et al. (2011). Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 117, 3302-3310. doi: 10.1182/blood-2010-09-310862
119. Kelland, L. R. (2000). Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin. Investig. Drugs 9, 2903-2911. doi: 10.1517/13543784.9.12.2903
120. Kim, S. H., and Ryan, T. A. (2010). CDK5 serves as a major control point in neurotransmitter release. Neuron 67, 797-809. doi: 10.1016/j.neuron.2010.08.003
121. Kim, S. J., Nakayama, S., Miyoshi, Y., Taguchi, T., Tamaki, Y., Matsushima, T., et al. (2008). Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann. Oncol. 19, 68-72. doi: 10.1093/annonc/mdm358
122. Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., et al. (2013). Abstract PR02: LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6-Reactivating Rb in cancer. Mol. Cancer Ther. 12:PR02. doi: 10.1158/1535-7163.TARG-13-PR02
123. Klinakis, A., Lobry, C., Abdel-Wahab, O., Oh, P., Haeno, H., Buonamici, S., et al. (2011). A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473, 230-233. doi: 10.1038/nature09999
124. Knuesel, M. T., Meyer, K. D., Bernecky, C., and Taatjes, D. J. (2009). The human CDK8 subcomplex is a molecular switch that controls Mediator coactivator function. Genes Dev. 23, 439-451. doi: 10.1101/gad.1767009
125. Ko, H. W., Norman, R. X., Tran, J., Fuller, K. P., Fukuda, M., and Eggenschwiler, J. T. (2010). Broad-minded links cell cycle-related kinase to cilia assembly and hedgehog signal transduction. Dev. Cell 18, 237-247. doi: 10.1016/j.devcel.2009.12.014
126. Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., et al. (2013). A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 24, 167-181. doi: 10.1016/j.ccr.2013.07.012
127. Kollmann, K., and Sexl, V. (2013). CDK6 and p16INK4A in lymphoid malignancies. Oncotarget 4, 1858-1859.
128. Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., et al. (2008). H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355-368. doi: 10.1016/j.ccr.2008.10.001
129. Kumar, S.K., Laplant, B., Chng, W.J., Zonder, J., Callander, N., Fonseca, R., et al. (2015). Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 125, 443-448. doi: 10.1182/blood-2014-05-573741
130. Kushner, J. A., Ciemerych, M. A., Sicinska, E., Wartschow, L. M., Teta, M., Long, S. Y., et al. (2005). Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol. Cell. Biol. 25, 3752-3762. doi: 10.1128/MCB.25.9.3752-3762.2005
131. Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., et al. (2014). Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616-620. doi: 10.1038/nature13393
132. Lal, S., Blanco, F., Yeo, T. P., Yeo, C. J., Brody, J. R., and Winter, J. M. (2014). Sequence alterations in the WEE1 non-coding region is a facilitator and marker for pancreatic tumorigenesis. Gastrointest. Endosc. 79, AB188. doi: 10.1016/j.gie.2014.02.234
133. Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., et al. (2001). Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2:RESEARCH0041. doi: 10.1186/gb-2001-2-10-research0041
134. Lapenna, S., and Giordano, A. (2009). Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547-566. doi: 10.1038/nrd2907
135. Lavoie, G., and St-Pierre, Y. (2011). Phosphorylation of human DNMT1: implication of cyclin-dependent kinases. Biochem. Biophys. Res. Commun. 409, 187-192. doi: 10.1016/j.bbrc.2011.04.115
136. Leclerc, V., Tassan, J. P., O'farrell, P. H., Nigg, E. A., and Leopold, P. (1996). Drosophila Cdk8, a kinase partner of cyclin C that interacts with the large subunit of RNA polymerase II. Mol. Biol. Cell 7, 505-513. doi: 10.1091/mbc.7.4.505
137. Leonard, J. P., Lacasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., et al. (2012). Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119, 4597-4607. doi: 10.1182/blood-2011-10-388298
138. Li, L., Wang, J., Hou, J., Wu, Z., Zhuang, Y., Lu, M., et al. (2012). Cdk1 interplays with Oct4 to repress differentiation of embryonic stem cells into trophectoderm. FEBS Lett. 586, 4100-4107. doi: 10.1016/j.febslet.2012.10.030
139. Li, N., Fassl, A., Chick, J., Inuzuka, H., Li, X., Mansour, M. R., et al. (2014). Cyclin C is a haploinsufficient tumour suppressor. Nat. Cell Biol. 16, 1080-1091. doi: 10.1038/ncb3046
140. Liao, S. M., Zhang, J., Jeffery, D. A., Koleske, A. J., Thompson, C. M., Chao, D. M., et al. (1995). A kinase-cyclin pair in the RNA polymerase II holoenzyme. Nature 374, 193-196. doi: 10.1038/374193a0
141. Lien, H. C., Lin, C. W., Huang, P. H., Chang, M. L., and Hsu, S. M. (2000). Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas. Lab. Invest. 80, 893-900. doi: 10.1038/labinvest.3780093
142. Lim, S., and Kaldis, P. (2013). Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140, 3079-3093. doi: 10.1242/dev.091744
143. Link, K. A., Chou, F. S., and Mulloy, J. C. (2010). Core binding factor at the crossroads: determining the fate of the HSC. J. Cell. Physiol. 222, 50-56. doi: 10.1002/jcp.21950
144. Lobo, N. A., Shimono, Y., Qian, D., and Clarke, M. F. (2007). The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 23, 675-699. doi: 10.1146/annurev.cellbio.22.010305.104154
145. Lu, F., Gladden, A. B., and Diehl, J. A. (2003). An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 63, 7056-7061.
146. Magnussen, G. I., Holm, R., Emilsen, E., Rosnes, A. K., Slipicevic, A., and Florenes, V. A. (2012). High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS ONE 7:e38254. doi: 10.1371/journal.pone.0038254
147. Malumbres, M., and Barbacid, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-166. doi: 10.1038/nrc2602
148. Malumbres, M., Sotillo, R., Santamaria, D., Galan, J., Cerezo, A., Ortega, S., et al. (2004). Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118, 493-504. doi: 10.1016/j.cell.2004.08.002
149. Manohar, S. M., Rathos, M. J., Sonawane, V., Rao, S. V., and Joshi, K. S. (2011). Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk. Res. 35, 821-830. doi: 10.1016/j.leukres.2010.12.010
150. Marais, A., Ji, Z., Child, E. S., Krause, E., Mann, D. J., and Sharrocks, A. D. (2010). Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK cyclin complexes. J. Biol. Chem. 285, 35728-35739. doi: 10.1074/jbc. M110.154005
151. Martin, A., Odajima, J., Hunt, S. L., Dubus, P., Ortega, S., Malumbres, M., et al. (2005). Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 7, 591-598. doi: 10.1016/j.ccr.2005.05.006
152. Martin, J., Hunt, S. L., Dubus, P., Sotillo, R., Nehme-Pelluard, F., Magnuson, M. A., et al. (2003). Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene 22, 5261-5269. doi: 10.1038/sj.onc.1206506
153. Martin, M. P., Olesen, S. H., Georg, G. I., and Schonbrunn, E. (2013). Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 8, 2360-2365. doi: 10.1021/cb4003283
154. Marzec, M., Kasprzycka, M., Lai, R., Gladden, A. B., Wlodarski, P., Tomczak, E., et al. (2006). Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 108, 1744-1750. doi: 10.1182/blood-2006-04-016634
155. Matsuda, S., Kominato, K., Koide-Yoshida, S., Miyamoto, K., Isshiki, K., Tsuji, A., et al. (2014). PCTAIRE kinase 3/cyclin-dependent kinase 18 is activated through association with cyclin A and/or phosphorylation by protein kinase A. J. Biol. Chem. 289, 18387-18400. doi: 10.1074/jbc. M113.542936
156. Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., and Elledge, S. J. (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 97, 10389-10394. doi: 10.1073/pnas.190030497
157. Mcgowan, C. H., and Russell, P. (1995). Cell cycle regulation of human WEE1. EMBO J. 14, 2166-2175.
158. Menu, E., Garcia, J., Huang, X., Di Liberto, M., Toogood, P. L., Chen, I., et al. (2008). A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res. 68, 5519-5523. doi: 10.1158/0008-5472.CAN-07-6404
159. Meshinchi, S., and Arceci, R. J. (2007). Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 12, 341-355. doi: 10.1634/theoncologist.12-3-341
160. Meyer, C., Hofmann, J., Burmeister, T., Groger, D., Park, T. S., Emerenciano, M., et al. (2013). The MLL recombinome of acute leukemias in 2013. Leukemia 27, 2165-2176. doi: 10.1038/leu.2013.135
161. Mikolcevic, P., Sigl, R., Rauch, V., Hess, M. W., Pfaller, K., Barisic, M., et al. (2012). Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis. Mol. Cell. Biol. 32, 868-879. doi: 10.1128/MCB.06261-11
162. Miyata, Y., Liu, Y., Jankovic, V., Sashida, G., Lee, J. M., Shieh, J. H., et al. (2010). Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells 28, 308-317. doi: 10.1002/stem.270
163. Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Muller, C., et al. (2000). Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96, 3907-3914.
164. Mizuki, M., Schwable, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., et al. (2003). Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 101, 3164-3173. doi: 10.1182/blood-2002-06-1677
165. Mohamedali, A., Soeiro, I., Lea, N. C., Glassford, J., Banerji, L., Mufti, G. J., et al. (2003). Cyclin D2 controls B cell progenitor numbers. J. Leukoc. Biol. 74, 1139-1143. doi: 10.1189/jlb.0803363
166. Moons, D. S., Jirawatnotai, S., Parlow, A. F., Gibori, G., Kineman, R. D., and Kiyokawa, H. (2002). Pituitary hypoplasia and lactotroph dysfunction in mice deficient for cyclin-dependent kinase-4. Endocrinology 143, 3001-3008. doi: 10.1210/endo.143.8.8956
167. Moore, A. S., Kearns, P. R., Knapper, S., Pearson, A. D., and Zwaan, C. M. (2013). Novel therapies for children with acute myeloid leukaemia. Leukemia 27, 1451-1460. doi: 10.1038/leu.2013.106
168. Morris, E. J., Ji, J. Y., Yang, F. J., Di Stefano, L., Herr, A., Moon, N. S., et al. (2008). E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 455, U552-U567. doi: 10.1038/nature07310
169. Motokura, T., and Arnold, A. (1993). Cyclin D and oncogenesis. Curr. Opin. Genet. Dev. 3, 5-10. doi: 10.1016/S0959-437X(05)80334-X
170. Mrozek, K., Heinonen, K., and Bloomfield, C. D. (2001). Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract. Res. Clin. Haematol. 14, 19-47. doi: 10.1053/beha.2000.0114
171. Nagel, S., Leich, E., Quentmeier, H., Meyer, C., Kaufmann, M., Drexler, H. G., et al. (2008). Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia 22, 387-392. doi: 10.1038/sj.leu.2405028
172. Napper, A. D., and Watson, V. G. (2013). Targeted drug discovery for pediatric leukemia. Front. Oncol. 3:170. doi: 10.3389/fonc.2013.00170
173. Neganova, I., Vilella, F., Atkinson, S. P., Lloret, M., Passos, J. F., Von Zglinicki, T., et al. (2011). An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells. Stem Cells 29, 651-659. doi: 10.1002/stem.620
174. Nelson, C., Goto, S., Lund, K., Hung, W., and Sadowski, I. (2003). Srb10/Cdk8 regulates yeast filamentous growth by phosphorylating the transcription factor Ste12. Nature 421, 187-190. doi: 10.1038/nature01243
175. Nigg, E. A. (1995). Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 17, 471-480. doi: 10.1002/bies.950170603
176. Nuchprayoon, I., Meyers, S., Scott, L. M., Suzow, J., Hiebert, S., and Friedman, A. D. (1994). PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol. Cell. Biol. 14, 5558-5568.
177. Odemuyiwa, S. O., Ilarraza, R., Davoine, F., Logan, M. R., Shayeganpour, A., Wu, Y., et al. (2015). Cyclin-dependent kinase 5 regulates degranulation in human eosinophils. Immunology 144, 641-648. doi: 10.1111/imm.12416
178. Orford, K. W., and Scadden, D. T. (2008). Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat. Rev. Genet. 9, 115-128. doi: 10.1038/nrg2269
179. Ortega, S., Prieto, I., Odajima, J., Martin, A., Dubus, P., Sotillo, R., et al. (2003). Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35, 25-31. doi: 10.1038/ng1232
180. Ortiz-Ruiz, M. J., Alvarez-Fernandez, S., Parrott, T., Zaknoen, S., Burrows, F. J., Ocana, A., et al. (2014). Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget 5, 11308-11318.
181. Otto, T., and Sicinski, P. (2013). The kinase-independent, second life of CDK6 in transcription. Cancer Cell 24, 141-143. doi: 10.1016/j.ccr.2013.07.019
182. Pallis, M., Abdul-Aziz, A., Burrows, F., Seedhouse, C., Grundy, M., and Russell, N. (2012). The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells. Br. J. Haematol. 159, 191-203. doi: 10.1111/bjh.12018
183. Park, M. H., Kim, S. Y., Kim, Y. J., and Chung, Y. H. (2014). ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34. Biochem. Biophys. Res. Commun. 450, 129-134. doi: 10.1016/j.bbrc.2014.05.070
184. Park, Y., and Gerson, S. L. (2005). DNA repair defects in stem cell function and aging. Annu. Rev. Med. 56, 495-508. doi: 10.1146/annurev.med.56.082103.104546
185. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., et al. (1998). Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91, 458-465.
186. Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., et al. (2010). Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther. 9, 2344-2353. doi: 10.1158/1535-7163.MCT-10-0324
187. Paruch, K., Dwyer, M. P., Alvarez, C., Brown, C., Chan, T. Y., Doll, R. J., et al. (2010). Discovery of Dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med. Chem. Lett. 1, 204-208. doi: 10.1021/ml100051d
188. Passegue, E., Wagers, A. J., Giuriato, S., Anderson, W. C., and Weissman, I. L. (2005). Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J. Exp. Med. 202, 1599-1611. doi: 10.1084/jem.20050967
189. Peyressatre, M., Prevel, C., Pellerano, M., and Morris, M. C. (2015). Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel). 7, 179-237. doi: 10.3390/cancers7010179
190. Phirke, P., Efimenko, E., Mohan, S., Burghoorn, J., Crona, F., Bakhoum, M. W., et al. (2011). Transcriptional profiling of C. elegans DAF-19 uncovers a ciliary base-associated protein and a CDK/CCRK/LF2p-related kinase required for intraflagellar transport. Dev. Biol. 357, 235-247. doi: 10.1016/j.ydbio.2011.06.028
191. Pietras, E. M., Warr, M. R., and Passegue, E. (2011). Cell cycle regulation in hematopoietic stem cells. J. Cell Biol. 195, 709-720. doi: 10.1083/jcb.201102131
192. Pitts, T. M., Davis, S. L., Eckhardt, S. G., and Bradshaw-Pierce, E. L. (2014). Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors. Pharmacol. Ther. 142, 258-269. doi: 10.1016/j.pharmthera.2013.12.010
193. Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., et al. (2014). Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 124, 13-23. doi: 10.1182/blood-2014-02-558114
194. Porter, C. C., Kim, J., Fosmire, S., Gearheart, C. M., Van Linden, A., Baturin, D., et al. (2012a). Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 26, 1266-1276. doi: 10.1038/leu.2011.392
195. Porter, D. C., Farmaki, E., Altilia, S., Schools, G. P., West, D. K., Chen, M., et al. (2012b). Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc. Natl. Acad. Sci. U.S.A. 109, 13799-13804. doi: 10.1073/pnas.1206906109
196. Posthumadeboer, J., Wurdinger, T., Graat, H. C., Van Beusechem, V. W., Helder, M. N., Van Royen, B. J., et al. (2011). WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 11:156. doi: 10.1186/1471-2407-11-156
197. Pui, C. H., Carroll, W. L., Meshinchi, S., and Arceci, R. J. (2011). Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29, 551-565. doi: 10.1200/JCO.2010.30.7405
198. Qi, W., Xie, C., Li, C., Caldwell, J. T., Edwards, H., Taub, J. W., et al. (2014). CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J. Hematol. Oncol. 7:53. doi: 10.1186/s13045-014-0053-9
199. Radomska, H. S., Alberich-Jorda, M., Will, B., Gonzalez, D., Delwel, R., and Tenen, D. G. (2012). Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPalpha. J. Clin. Invest. 122, 2955-2966. doi: 10.1172/JCI43354
200. Radomska, H. S., Basseres, D. S., Zheng, R., Zhang, P., Dayaram, T., Yamamoto, Y., et al. (2006). Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J. Exp. Med. 203, 371-381. doi: 10.1084/jem.20052242
201. Raje, N., Hideshima, T., Mukherjee, S., Raab, M., Vallet, S., Chhetri, S., et al. (2009). Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 23, 961-970. doi: 10.1038/leu.2008.378
202. Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., et al. (1999). Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat. Genet. 22, 44-52. doi: 10.1038/8751
203. Rathos, M. J., Khanwalkar, H., Joshi, K., Manohar, S. M., and Joshi, K. S. (2013). Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer 13:29. doi: 10.1186/1471-2407-13-29
204. Ray, D., Terao, Y., Christov, K., Kaldis, P., and Kiyokawa, H. (2011). Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis. Neoplasia 13, 439-444.
205. Redondo, J. M., Pfohl, J. L., Hernandez-Munain, C., Wang, S., Speck, N. A., and Krangel, M. S. (1992). Indistinguishable nuclear factor binding to functional core sites of the T-cell receptor delta and murine leukemia virus enhancers. Mol. Cell. Biol. 12, 4817-4823.
206. Ren, S., and Rollins, B. J. (2004). Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 117, 239-251. doi: 10.1016/S0092-8674(04)00300-9
207. Renneville, A., Roumier, C., Biggio, V., Nibourel, O., Boissel, N., Fenaux, P., et al. (2008). Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 22, 915-931. doi: 10.1038/leu.2008.19
208. Rickert, P., Seghezzi, W., Shanahan, F., Cho, H., and Lees, E. (1996). Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene 12, 2631-2640.
209. Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., et al. (2012). Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J. Natl. Cancer Inst. 104, 476-487. doi: 10.1093/jnci/djs002
210. Rombouts, W. J., Blokland, I., Lowenberg, B., and Ploemacher, R. E. (2000). Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14, 675-683. doi: 10.1038/sj.leu.2401731
211. Ross, S. E., Radomska, H. S., Wu, B., Zhang, P., Winnay, J. N., Bajnok, L., et al. (2004). Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol. Cell. Biol. 24, 675-686. doi: 10.1128/MCB.24.2.675-686.2004
212. Sanchez-Martinez, C., Gelbert, L. M., Shannon, H., De Dios, A., Staton, B. A., Ajamie, R. T., et al. (2011). Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. Mol. Cancer Ther. 10:B234. doi: 10.1158/1535-7163.TARG-11-B234
213. Santamaria, D., Barriere, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., et al. (2007). Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448, 811-815. doi: 10.1038/nature06046
214. Santo, L., Vallet, S., Hideshima, T., Cirstea, D., Ikeda, H., Pozzi, S., et al. (2010). AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 29, 2325-2336. doi: 10.1038/onc.2009.510
215. Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brustle, A., et al. (2012). IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656-659. doi: 10.1038/nature11323
216. Satyanarayana, A., Hilton, M. B., and Kaldis, P. (2008). p21 Inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint. Mol. Biol. Cell 19, 65-77. doi: 10.1091/mbc. E07-06-0525
217. Satyanarayana, A., and Kaldis, P. (2009). A dual role of Cdk2 in DNA damage response. Cell Div. 4:9. doi: 10.1186/1747-1028-4-9
218. Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., et al. (2012). Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell 22, 452-465. doi: 10.1016/j.ccr.2012.09.016
219. Scaltriti, M., Eichhorn, P. J., Cortes, J., Prudkin, L., Aura, C., Jimenez, J., et al. (2011). Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc. Natl. Acad. Sci. U.S.A. 108, 3761-3766. doi: 10.1073/pnas.1014835108
220. Scheicher, R., Hoelbl-Kovacic, A., Bellutti, F., Tigan, A. S., Prchal-Murphy, M., Heller, G., et al. (2015). CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 125, 90-101. doi: 10.1182/blood-2014-06-584417
221. Schnerch, D., Yalcintepe, J., Schmidts, A., Becker, H., Follo, M., Engelhardt, M., et al. (2012). Cell cycle control in acute myeloid leukemia. Am. J. Cancer Res. 2, 508-528.
222. Schnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., et al. (2011). RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 117, 2348-2357. doi: 10.1182/blood-2009-11-255976
223. Schwartz, G. K., Lorusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., et al. (2011). Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br. J. Cancer 104, 1862-1868. doi: 10.1038/bjc.2011.177
224. Schwartz, R., Engel, I., Fallahi-Sichani, M., Petrie, H. T., and Murre, C. (2006). Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development. Proc. Natl. Acad. Sci. U.S.A. 103, 9976-9981. doi: 10.1073/pnas.0603728103
225. Sedlacek, H. H. (2001). Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 38, 139-170. doi: 10.1016/S1040-8428(00)00124-4
226. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., et al. (1998). Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 16, 2986-2999.
227. Shapiro, G. I. (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770-1783. doi: 10.1200/JCO.2005.03.7689
228. Shapiro, G., Rosen, L. S., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., et al. (2013). A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J. Clin. Oncol. 31, 2013(suppl.):Abstract 2500.
229. Sheppard, K. E., and Mcarthur, G. A. (2013). The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin. Cancer Res. 19, 5320-5328. doi: 10.1158/1078-0432.CCR-13-0259
230. Sherr, C. J., and Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512. doi: 10.1101/gad.13.12.1501
231. Shiekhattar, R., Mermelstein, F., Fisher, R. P., Drapkin, R., Dynlacht, B., Wessling, H. C., et al. (1995). Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature 374, 283-287. doi: 10.1038/374283a0
232. Shih, A. H., Abdel-Wahab, O., Patel, J. P., and Levine, R. L. (2012). The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12, 599-612. doi: 10.1038/nrc3343
233. Shirsath, N. P., Manohar, S. M., and Joshi, K. S. (2012). P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Mol. Cancer 11:77. doi: 10.1186/1476-4598-11-77
234. Shtivelman, E., Lifshitz, B., Gale, R. P., and Canaani, E. (1985). Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315, 550-554. doi: 10.1038/315550a0
235. Sicinska, E., Aifantis, I., Le Cam, L., Swat, W., Borowski, C., Yu, Q., et al. (2003). Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451-461. doi: 10.1016/S1535-6108(03)00301-5
236. Small, D. (2006). FLT3 mutations: biology and treatment. Hematology Am. Soc. Hematol. Educ. Program 2006, 178-184. doi: 10.1182/asheducation-2006.1.178
237. Smith, A., Howell, D., Patmore, R., Jack, A., and Roman, E. (2011). Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br. J. Cancer 105, 1684-1692. doi: 10.1038/bjc.2011.450
238. Smolewski, P. (2008). Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 11, 204-214.
239. Solomon, D. A., Wang, Y., Fox, S. R., Lambeck, T. C., Giesting, S., Lan, Z., et al. (2003). Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J. Biol. Chem. 278, 30339-30347. doi: 10.1074/jbc. M303969200
240. Sonoki, T., Harder, L., Horsman, D. E., Karran, L., Taniguchi, I., Willis, T. G., et al. (2001). Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood 98, 2837-2844. doi: 10.1182/blood. V98.9.2837
241. Spiekermann, K., Bagrintseva, K., Schwab, R., Schmieja, K., and Hiddemann, W. (2003). Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin. Cancer Res. 9, 2140-2150.
242. Squires, M. S., Cooke, L., Lock, V., Qi, W., Lewis, E. J., Thompson, N. T., et al. (2010). AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol. Cancer Ther. 9, 920-928. doi: 10.1158/1535-7163.MCT-09-1071
243. Squires, M. S., Feltell, R. E., Wallis, N. G., Lewis, E. J., Smith, D. M., Cross, D. M., et al. (2009). Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol. Cancer Ther. 8, 324-332. doi: 10.1158/1535-7163.MCT-08-0890
244. Szilagyi, Z., and Gustafsson, C. M. (2013). Emerging roles of Cdk8 in cell cycle control. Biochim. Biophys. Acta 1829, 916-920. doi: 10.1016/j.bbagrm.2013.04.010
245. Taneera, J., Fadista, J., Ahlqvist, E., Zhang, M., Wierup, N., Renstrom, E., et al. (2013). Expression profiling of cell cycle genes in human pancreatic islets with and without type 2 diabetes. Mol. Cell. Endocrinol. 375, 35-42. doi: 10.1016/j.mce.2013.05.003
246. Tassan, J. P., Jaquenoud, M., Leopold, P., Schultz, S. J., and Nigg, E. A. (1995). Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. Proc. Natl. Acad. Sci. U.S.A. 92, 8871-8875. doi: 10.1073/pnas.92.19.8871
247. Tenen, D. G. (2003). Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 3, 89-101. doi: 10.1038/nrc989
248. Tesio, M., and Trumpp, A. (2011). Breaking the cell cycle of HSCs by p57 and friends. Cell Stem Cell 9, 187-192. doi: 10.1016/j.stem.2011.08.005
249. Thompson, B. J., Buonamici, S., Sulis, M. L., Palomero, T., Vilimas, T., Basso, G., et al. (2007). The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825-1835. doi: 10.1084/jem.20070872
250. Tibes, R., Bogenberger, J. M., Chaudhuri, L., Hagelstrom, R. T., Chow, D., Buechel, M. E., et al. (2012). RNAi screening of the kinome with cytarabine in leukemias. Blood 119, 2863-2872. doi: 10.1182/blood-2011-07-367557
251. Tibes, R., Kornblau, S. M., Qiu, Y., Mousses, S. M., Robbins, C., Moses, T., et al. (2008). PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br. J. Haematol. 140, 344-347. doi: 10.1111/j.1365-2141.2007.06920.x
252. Tibes, R., Mcdonagh, K. T., Lekakis, L., Bogenberger, J. M., Kim, S., Frazer, N., et al. (2014). Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. Invest. New Drugs. doi: 10.1007/s10637-014-0198-y. [Epub ahead of print].
253. Tohda, S., Kogoshi, H., Murakami, N., Sakano, S., and Nara, N. (2005). Diverse effects of the Notch ligands Jagged1 and Delta1 on the growth and differentiation of primary acute myeloblastic leukemia cells. Exp. Hematol. 33, 558-563. doi: 10.1016/j.exphem.2005.01.010
254. Tomashevski, A., Webster, D. R., Grammas, P., Gorospe, M., and Kruman, II. (2010). Cyclin-C-dependent cell-cycle entry is required for activation of non-homologous end joining DNA repair in postmitotic neurons. Cell Death Differ. 17, 1189-1198. doi: 10.1038/cdd.2009.221
255. Tominaga, Y., Li, C., Wang, R. H., and Deng, C. X. (2006). Murine Wee1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development. Int. J. Biol. Sci. 2, 161-170. doi: 10.7150/ijbs.2.161
256. Trakala, M., and Malumbres, M. (2014). Cyclin C surprises in tumour suppression. Nat. Cell Biol. 16, 1031-1033. doi: 10.1038/ncb3055
257. Tse, K. F., Mukherjee, G., and Small, D. (2000). Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14, 1766-1776. doi: 10.1038/sj.leu.2401905
258. Tsutsui, T., Hesabi, B., Moons, D. S., Pandolfi, P. P., Hansel, K. S., Koff, A., et al. (1999). Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol. Cell. Biol. 19, 7011-7019.
259. Van Der Biessen, D. A., Burger, H., De Bruijn, P., Lamers, C. H., Naus, N., Loferer, H., et al. (2014). Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors. Clin. Cancer Res. 20, 4776-4783. doi: 10.1158/1078-0432.CCR-14-0325
260. Van Der Linden, M. H., Willekes, M., Van Roon, E., Seslija, L., Schneider, P., Pieters, R., et al. (2014). MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle 13, 834-844. doi: 10.4161/cc.27757
261. Van Linden, A. A., Baturin, D., Ford, J. B., Fosmire, S. P., Gardner, L., Korch, C., et al. (2013). Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol. Cancer Ther. 12, 2675-2684. doi: 10.1158/1535-7163.MCT-13-0424
262. Wakita, S., Yamaguchi, H., Omori, I., Terada, K., Ueda, T., Manabe, E., et al. (2013). Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia 27, 1044-1052. doi: 10.1038/leu.2012.317
263. Walsby, E., Pratt, G., Shao, H., Abbas, A. Y., Fischer, P. M., Bradshaw, T. D., et al. (2014). A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget 5, 375-385.
264. Wang, J. C., and Dick, J. E. (2005). Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494-501. doi: 10.1016/j.tcb.2005.07.004
265. Wang, J., Zhao, Y., Wang, Y., and Huang, J. (2013). Molecular dynamics simulations and statistical coupling analysis reveal functional coevolution network of oncogenic mutations in the CDKN2A-CDK6 complex. FEBS Lett. 587, 136-141. doi: 10.1016/j.febslet.2012.11.001
266. Wang, L., Wang, J., Blaser, B. W., Duchemin, A. M., Kusewitt, D. F., Liu, T., et al. (2007). Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 110, 2075-2083. doi: 10.1182/blood-2007-02-071266
267. Wang, Q., Su, L., Liu, N., Zhang, L., Xu, W., and Fang, H. (2011). Cyclin dependent kinase 1 inhibitors: a review of recent progress. Curr. Med. Chem. 18, 2025-2043. doi: 10.2174/092986711795590110
268. Wang, Y., Decker, S. J., and Sebolt-Leopold, J. (2004). Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol. Ther. 3, 305-313. doi: 10.4161/cbt.3.3.697
269. Wang, Y., Li, J., Booher, R. N., Kraker, A., Lawrence, T., Leopold, W. R., et al. (2001). Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 61, 8211-8217.
270. Waraky, A., Akopyan, K., Parrow, V., Stromberg, T., Axelson, M., Abrahmsen, L., et al. (2014). Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism. Oncotarget 5, 8379-8392.
271. Wei, Y., Chen, Y. H., Li, L. Y., Lang, J., Yeh, S. P., Shi, B., et al. (2011). CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol. 13, 87-94. doi: 10.1038/ncb2139
272. Weisberg, E., Nonami, A., Chen, Z., Liu, F., Zhang, J., Sattler, M., et al. (2015). Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia 29, 27-37. doi: 10.1038/leu.2014.149
273. Weissman, I. L. (2000). Stem cells: units of development, units of regeneration, and units in evolution. Cell 100, 157-168. doi: 10.1016/S0092-8674(00)81692-X
274. Wiest, T., Schwarz, E., Enders, C., Flechtenmacher, C., and Bosch, F. X. (2002). Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21, 1510-1517. doi: 10.1038/sj.onc.1205214
275. William, A. D., Lee, A. C., Goh, K. C., Blanchard, S., Poulsen, A., Teo, E. L., et al. (2012). Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptaco sa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J. Med. Chem. 55, 169-196. doi: 10.1021/jm201112g
276. Wilson, A., Laurenti, E., Oser, G., Van Der Wath, R. C., Blanco-Bose, W., Jaworski, M., et al. (2008). Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118-1129. doi: 10.1016/j.cell.2008.10.048
277. Wohlbold, L., Larochelle, S., Liao, J. C. F., Livshits, G., Singer, J., Shokat, K. M., et al. (2006). The cyclin-dependent kinase (CDK) family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity. Cell Cycle 5, 546-554. doi: 10.4161/cc.5.5.2541
278. Wohlbold, L., Merrick, K. A., De, S., Amat, R., Kim, J. H., Larochelle, S., et al. (2012). Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cells. PLoS Genet. 8:e1002935. doi: 10.1371/journal.pgen.1002935
279. Wu, Z., Doondeea, J. B., Gholami, A. M., Janning, M. C., Lemeer, S., Kramer, K., et al. (2011). Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol. Cell. Proteomics 10:M111 011635. doi: 10.1074/mcp. M111.011635
280. Xu, J., Wang, Y. Y., Dai, Y. J., Zhang, W., Zhang, W. N., Xiong, S. M., et al. (2014). DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc. Natl. Acad. Sci. U.S.A. 111, 2620-2625. doi: 10.1073/pnas.1400150111
281. Yang, Y., Roine, N., and Makela, T. P. (2013a). CCRK depletion inhibits glioblastoma cell proliferation in a cilium-dependent manner. EMBO Rep. 14, 741-747. doi: 10.1038/embor.2013.80
282. Yang, Z., Yang, C., Zhang, S., Li, Y., and Chen, J. (2013b). Notch2 inhibits proliferation of chronic myeloid leukemia cells. Oncol. Lett. 5, 1390-1394. doi: 10.3892/ol.2013.1159
283. Yin, D. D., Fan, F. Y., Hu, X. B., Hou, L. H., Zhang, X. P., Liu, L., et al. (2009). Notch signaling inhibits the growth of the human chronic myeloid leukemia cell line K562. Leuk. Res. 33, 109-114. doi: 10.1016/j.leukres.2008.06.023
284. Yu, D. S., Zhao, R., Hsu, E. L., Cayer, J., Ye, F., Guo, Y., et al. (2010). Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. EMBO Rep. 11, 876-882. doi: 10.1038/embor.2010.153
285. Yu, Q., Sicinska, E., Geng, Y., Ahnstrom, M., Zagozdzon, A., Kong, Y., et al. (2006). Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23-32. doi: 10.1016/j.ccr.2005.12.012
286. Zeestraten, E. C., Maak, M., Shibayama, M., Schuster, T., Nitsche, U., Matsushima, T., et al. (2012). Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br. J. Cancer 106, 133-140. doi: 10.1038/bjc.2011.504
287. Zhang, C., Elkahloun, A. G., Robertson, M., Gills, J. J., Tsurutani, J., Shih, J. H., et al. (2011). Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. PLoS ONE 6:e23849. doi: 10.1371/journal.pone.0023849
288. Zhang, D. E., Fujioka, K., Hetherington, C. J., Shapiro, L. H., Chen, H. M., Look, A. T., et al. (1994). Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol. Cell. Biol. 14, 8085-8095.
289. Zhang, L., Fried, F. B., Guo, H., and Friedman, A. D. (2008). Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood 111, 1193-1200. doi: 10.1182/blood-2007-08-109702
290. Zhao, X., Feng, D., Wang, Q., Abdulla, A., Xie, X. J., Zhou, J., et al. (2012). Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. J. Clin. Invest. 122, 2417-2427. doi: 10.1172/JCI61462
291. Zhou, L., Zhang, Y., Chen, S., Kmieciak, M., Leng, Y., Lin, H., et al. (2014). A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia. doi: 10.1038/leu.2014.296. [Epub ahead of print].